Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
HR, hazard ratio
LOCF, last observation carried forward
PASI, psoriasis area and severity index
PP, per protocol
PsoRA, Psoriasis Registry Austria
SD, standard deviation
apremilast
drug survival
psoriasis
Journal
JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
accepted:
18
10
2020
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction. This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry. Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment. Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.
OBJECTIVE
OBJECTIVE
To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.
METHODS
METHODS
This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.
RESULTS
RESULTS
Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49,
LIMITATIONS
CONCLUSIONS
Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.
CONCLUSION
CONCLUSIONS
Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.
Identifiants
pubmed: 34409355
doi: 10.1016/j.jdin.2020.10.012
pii: S2666-3287(20)30071-7
pmc: PMC8362309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62-75Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.
Références
Arthritis Res Ther. 2019 May 10;21(1):118
pubmed: 31077258
J Invest Dermatol. 2015 Nov;135(11):2641-2648
pubmed: 26046458
J Eur Acad Dermatol Venereol. 2013 Jul;27(7):861-6
pubmed: 22672248
BMC Dermatol. 2018 Jul 11;18(1):5
pubmed: 29996929
Clin Exp Dermatol. 2017 Aug;42(6):675-676
pubmed: 28621002
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e705-e707
pubmed: 32277507
JAMA Dermatol. 2018 May 1;154(5):581-588
pubmed: 29590279
RMD Open. 2018 Jun 27;4(1):e000669
pubmed: 30018799
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2821-2829
pubmed: 32271966
J Cutan Med Surg. 2018 May/Jun;22(3):290-296
pubmed: 29373924
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):254-259
pubmed: 28925560
Br J Dermatol. 2019 Jan;180(1):15-16
pubmed: 30604556
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708
pubmed: 30388318
Biologicals. 2018 Jul;54:44-49
pubmed: 29706309
J Am Acad Dermatol. 2018 Apr;78(4):801-803
pubmed: 29017843
J Dermatolog Treat. 2021 Mar;32(2):203-211
pubmed: 31769703
J Dtsch Dermatol Ges. 2019 May;17(5):503-516
pubmed: 30994260
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):293-300
pubmed: 31419355
J Am Acad Dermatol. 2015 Jul;73(1):37-49
pubmed: 26089047
Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12
pubmed: 30775293
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):e393-e394
pubmed: 29730885
J Dermatolog Treat. 2020 Apr 2;:1-15
pubmed: 32202445
J Dermatolog Treat. 2020 May 25;:1-6
pubmed: 32419531
J Dermatolog Treat. 2021 Sep;32(6):595-602
pubmed: 31714168
Br J Dermatol. 2019 Sep;181(3):450-458
pubmed: 30729500
Br J Dermatol. 2019 Jan;180(1):86-93
pubmed: 29791721
J Med Econ. 2019 Apr;22(4):365-371
pubmed: 30652520
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):245-253
pubmed: 28898541
Curr Med Res Opin. 2020 Jan;36(1):169-176
pubmed: 31517542
Br J Dermatol. 2011 Sep;165(3):640-5
pubmed: 21564068
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1214-1223
pubmed: 31037770
J Dermatolog Treat. 2019 Jun;30(4):383-386
pubmed: 30221571
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2390-8
pubmed: 26370908
Br J Dermatol. 2020 Mar;182(3):690-697
pubmed: 31021438
Br J Dermatol. 2014 Oct;171(4):915-7
pubmed: 24665924
Acta Derm Venereol. 2019 Dec 1;99(13):1224-1230
pubmed: 31580465
Int J Dermatol. 2019 Jun;58(6):631-641
pubmed: 30973647
Acta Derm Venereol. 2015 Nov;95(8):973-7
pubmed: 25950855
Dermatol Ther. 2020 May;33(3):e13440
pubmed: 32306448
J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151
pubmed: 27846617
J Dermatol. 2019 Jul;46(7):615-617
pubmed: 31180150
Acta Derm Venereol. 2016 Feb;96(2):207-12
pubmed: 26271044
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1173-1179
pubmed: 29388335
Br J Dermatol. 2015 Dec;173(6):1387-99
pubmed: 26357944
Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18
pubmed: 30578464